AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29211857 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-life scores in ADT ON group
Number of subjects: 153
Study 29211857 — intervention group
Group type: COMPARATOR
Intervention: Quality-of-life scores in ADT OFF group
Number of subjects: 153
Study 28700482 — intervention group
Group type: EXPERIMENTAL
Intervention: Fu-Zheng-Qu-Zhuo oral liquid (FZQZ)
Number of subjects: 68
Study 28700482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 23816199 — intervention group
Group type: EXPERIMENTAL
Intervention: Aftercare services including treatment follow-up (home care or telephone follow-up), family psychoeducation, and patient social skills training provided by community mental health teams.
Number of subjects: 0
Study 23816199 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 23816199 — intervention group
Group type: EXPERIMENTAL
Intervention: Aftercare services
Number of subjects: 0
Study 21714999 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD‐alum (20 μg, three injections)
Number of subjects: 145
Study 21714999 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD‐alum plus alum (20 μg GAD‐alum, two injections and one of alum)
Number of subjects: 145
Study 21714999 — intervention group
Group type: COMPARATOR
Intervention: Alum (three injections)
Number of subjects: 145
Study 21714999 — intervention group
Group type: COMPARATOR
Intervention: GAD‐alum vs alum
Number of subjects: 145
Study 21714999 — intervention group
Group type: COMPARATOR
Intervention: GAD‐alum plus alum vs alum
Number of subjects: 145
Study 21714999 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 145
Study 19400340 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing training
Number of subjects: 0
Study 19400340 — intervention group
Group type: COMPARATOR
Intervention: Asthma education (control)
Number of subjects: 0
Study 16671517 — intervention group
Group type: EXPERIMENTAL
Intervention: Uvulopalatopharyngoplasty with uvula preservation
Number of subjects: 46
Study 16671517 — intervention group
Group type: EXPERIMENTAL
Intervention: Uvulopalatopharyngoplasty with uvula preservation and radiofrequency tongue base reduction
Number of subjects: 46
Study 16671517 — intervention group
Group type: COMPARATOR
Intervention: Both groups (comparison)
Number of subjects: 46
Study 15541202 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-eliciting transcutaneous electrical stimulation (TES)
Number of subjects: 12
Study 15541202 — intervention group
Group type: COMPARATOR
Intervention: Non-pain transcutaneous electrical stimulation (TES)
Number of subjects: 12
Study 11385210 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinoid group
Number of subjects: 1219
Study 11385210 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo group
Number of subjects: 1219
Study 11385210 — intervention group
Group type: COMPARATOR
Intervention: PC patients
Number of subjects: 1219
Study 9203944 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (16-19 mmol/l glucose)
Number of subjects: 8
Study 9203944 — intervention group
Group type: COMPARATOR
Intervention: Euglycaemia (5-8 mmol/l glucose)
Number of subjects: 8
Study 7950736 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1 g twice daily)
Number of subjects: 25
Study 7950736 — intervention group
Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drug (diclofenac 50 mg twice daily)
Number of subjects: 25
Study 3389899 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Silastic catheters
Number of subjects: 0
Study 3389899 — intervention group
Group type: COMPARATOR
Intervention: Conventional intravenous cannulae
Number of subjects: 0
Study 30725537 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA-rich diet
Number of subjects: 47
Study 30725537 — intervention group
Group type: EXPERIMENTAL
Intervention: MED diet
Number of subjects: 47
Study 30725537 — intervention group
Group type: COMPARATOR
Intervention: Saturated fatty acid rich diet
Number of subjects: 47
Study 28419824 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone treatment for 12 weeks
Number of subjects: 56
Study 28419824 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 56
Study 26742304 — intervention group
Group type: EXPERIMENTAL
Intervention: HANS group (DC pulse stimulation at acupoints JiaJi and Ciliao, 100 Hz, 15-30 mA for 30 min)
Number of subjects: 120
Study 26742304 — intervention group
Group type: EXPERIMENTAL
Intervention: PCIA group (Ondansetron 8 mg IV for 5 min, tramadol 1.5 mg/kg infusion)
Number of subjects: 120
Study 26742304 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA group (Ropivacaine 3 mg intrathecal, epidural infusion of Ropivacaine 0.1% and Sufentanil 50 ug)
Number of subjects: 120
Study 26742304 — intervention group
Group type: COMPARATOR
Intervention: Control group (no analgesia)
Number of subjects: 120
Study 23411533 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 117
Study 23411533 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 117
Study 21757910 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) insufflation
Number of subjects: 60
Study 21757910 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 60
Study 18595519 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypotension group
Number of subjects: 60
Study 18595519 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 22472546 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs10273424
Number of subjects: 729
Study 15943962 — intervention group
Group type: EXPERIMENTAL
Intervention: Average pain levels for 'very satisfied' patients
Number of subjects: 207
Study 15943962 — intervention group
Group type: EXPERIMENTAL
Intervention: Average pain levels for 'somewhat satisfied' patients
Number of subjects: 207
Study 15943962 — intervention group
Group type: EXPERIMENTAL
Intervention: Average pain levels for 'slightly satisfied', 'neither satisfied nor dissatisfied', 'slightly dissatisfied', 'somewhat dissatisfied', and 'very dissatisfied' patients
Number of subjects: 207
Study 12571176 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous pigtail catheter drainage
Number of subjects: 26
Study 12571176 — intervention group
Group type: COMPARATOR
Intervention: Control group (hospitalized patients)
Number of subjects: 26
Study 12571176 — intervention group
Group type: COMPARATOR
Intervention: Control group (outpatient management)
Number of subjects: 26
Study 9871431 — intervention group
Group type: COMPARATOR
Intervention: zolpidem plus placebo
Number of subjects: 12
Study 9871431 — intervention group
Group type: EXPERIMENTAL
Intervention: zolpidem plus ketoconazole
Number of subjects: 12
Study 9871431 — intervention group
Group type: EXPERIMENTAL
Intervention: zolpidem plus itraconazole
Number of subjects: 12
Study 9871431 — intervention group
Group type: EXPERIMENTAL
Intervention: zolpidem plus fluconazole
Number of subjects: 12
Study 9098295 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (Genesis) technique of radial keratotomy
Number of subjects: 375
Study 2815966 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent split virus vaccine
Number of subjects: 140
Study 2815966 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent A/Taiwan/86(H1N1) vaccine
Number of subjects: 140
Study 782310 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 15
Study 782310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31663462 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Pill Bottle (SPB) with pharmacist intervention
Number of subjects: 40
Study 31663462 — intervention group
Group type: COMPARATOR
Intervention: Control group with deactivated alerts in SPBs
Number of subjects: 40
Study 29354972 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of central‐square needling technique of thumb‐tack needles with routine therapy of acupuncture, moxibustion and tuina
Number of subjects: 120
Study 29354972 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy of acupuncture, moxibustion and tuina
Number of subjects: 120
Study 29354972 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 29354972 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation group
Number of subjects: 120
Study 29354972 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 26219242 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 50
Study 26219242 — intervention group
Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 50
Study 23242570 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA(®) cream (2.5 g applied for a minimum of 30 min before venipuncture)
Number of subjects: 195
Study 23242570 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver during venipuncture
Number of subjects: 195
Study 23242570 — intervention group
Group type: COMPARATOR
Intervention: Vaseline(®) (control group)
Number of subjects: 195
Study 21667210 — intervention group
Group type: EXPERIMENTAL
Intervention: LESS TEP inguinal hernia repair
Number of subjects: 54
Study 21667210 — intervention group
Group type: COMPARATOR
Intervention: Standard TEP inguinal hernia repair
Number of subjects: 54
Study 18362868 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐MPH‐ER (20 mg/day)
Number of subjects: 82
Study 18362868 — intervention group
Group type: EXPERIMENTAL
Intervention: d,l‐MPH‐ER (36 mg/day)
Number of subjects: 82
Study 18362868 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐MPH‐ER and d,l‐MPH‐ER
Number of subjects: 82
Study 18362868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 16412546 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical neuroleptics (risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole)
Number of subjects: 37
Study 16412546 — intervention group
Group type: EXPERIMENTAL
Intervention: High potency neuroleptic agents (risperidone/ziprasidone/aripiprazole)
Number of subjects: 37
Study 16412546 — intervention group
Group type: EXPERIMENTAL
Intervention: Low potency neuroleptic agents (quetiapine/olanzapine)
Number of subjects: 37
Study 16412546 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical neuroleptics
Number of subjects: 37
Study 12937308 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg) and clopidogrel (75 mg) daily
Number of subjects: 200
Study 12937308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 12937308 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel
Number of subjects: 200
Study 11012555 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride 550 mg in solution alone
Number of subjects: 11
Study 11012555 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride 550 mg in solution after 10 mg i.v. dose of metoclopramide
Number of subjects: 11
Study 11012555 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride 550 mg in solution after 30 mg oral dose of propantheline
Number of subjects: 11
Study 8598838 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir (1800 mg per day) plus zidovudine (600 mg per day) and zalcitabine (2.25 mg per day)
Number of subjects: 302
Study 8598838 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine plus either saquinavir or zalcitabine
Number of subjects: 302
Study 8598838 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug combination (saquinavir, zidovudine, zalcitabine)
Number of subjects: 302
Study 8598838 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine and either saquinavir or zalcitabine
Number of subjects: 302
Study 1412099 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask without Venturi attachment at 2, 4, and 6 l/min
Number of subjects: 12
Study 1412099 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask with Venturi attachments (24% and 28%) at 2 and 4 l/min
Number of subjects: 12
Study 6443774 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefsulodin (various dosages, including 250 mg every 6 hr)
Number of subjects: 74
Study 6443774 — intervention group
Group type: COMPARATOR
Intervention: Aminoglycoside (gentamicin, tobramycin, or amikacin)
Number of subjects: 74
Study 28231811 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical somatosensory stimulation (ESS) plus usual rehabilitation
Number of subjects: 102
Study 28231811 — intervention group
Group type: COMPARATOR
Intervention: Sham electrical somatosensory stimulation (sham ESS) plus usual rehabilitation
Number of subjects: 102
Study 26138593 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab 25 mg plus MTX
Number of subjects: 418
Study 26138593 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab 100 mg plus MTX
Number of subjects: 418
Study 26138593 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab 200 mg plus MTX
Number of subjects: 418
Study 26138593 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab 100 mg monotherapy
Number of subjects: 418
Study 26138593 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab 200 mg monotherapy
Number of subjects: 418
Study 26138593 — intervention group
Group type: COMPARATOR
Intervention: MTX alone (Control)
Number of subjects: 418
Study 26138593 — intervention group
Group type: EXPERIMENTAL
Intervention: All clazakizumab groups (25 mg, 100 mg, 200 mg)
Number of subjects: 418
Study 26138593 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab treatment groups
Number of subjects: 418
Study 23207420 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial removal of carious dentine (PDR)
Number of subjects: 299
Study 23207420 — intervention group
Group type: COMPARATOR
Intervention: Stepwise excavation (SW)
Number of subjects: 299
Study 21170827 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 50
Study 21170827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19086197 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D surgical planning using 3D models constructed from CT and MRI data
Number of subjects: 40
Study 19086197 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D surgical planning using 3D models
Number of subjects: 40
Study 17169177 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching (qLZT-AH) of cryopreserved-thawed embryos (350 embryos)
Number of subjects: 702
Study 17169177 — intervention group
Group type: COMPARATOR
Intervention: Intact zona embryos (352 embryos)
Number of subjects: 702
Study 15585557 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (Te)
Number of subjects: 7
Study 15585557 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 7
Study 11518061 — intervention group
Group type: EXPERIMENTAL
Intervention: WS 5570 Hypericum perforatum extract 300 mg
Number of subjects: 12
Study 11518061 — intervention group
Group type: EXPERIMENTAL
Intervention: WS 5570 Hypericum perforatum extract 600 mg
Number of subjects: 12
Study 11518061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9453276 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 5 mg
Number of subjects: 247
Study 9453276 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 10 mg
Number of subjects: 247
Study 9453276 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 247
Study 8181115 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal proANF measurement
Number of subjects: 246
Study 3038431 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (EN)
Number of subjects: 0
Study 3038431 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (PPL)
Number of subjects: 0
Study 29319408 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremella fuciformis 600 mg/day, n=30
Number of subjects: 75
Study 29319408 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremella fuciformis 1200 mg/day, n=30
Number of subjects: 75
Study 29319408 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremella fuciformis (both doses combined)
Number of subjects: 75
Study 29319408 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n=15
Number of subjects: 75
Study 29319408 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremella fuciformis (both doses)
Number of subjects: 75
Study 28034373 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital body weight change (defined as the difference between baseline and discharge/day 10)
Number of subjects: 4172
Study 28034373 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight change by discharge/day 10
Number of subjects: 4172
Study 28034373 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight change during hospitalization
Number of subjects: 4172
Study 28034373 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight change post-discharge (>1-kg increase)
Number of subjects: 4172
Study 26571900 — intervention group
Group type: EXPERIMENTAL
Intervention: Shujing massage therapy
Number of subjects: 80
Study 26571900 — intervention group
Group type: COMPARATOR
Intervention: Medication with estazolam (1 mg orally before sleep)
Number of subjects: 80
Study 23532011 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS over the contralesional primary motor cortex followed by intermittent theta burst stimulation over the ipsilesional M1 (group A)
Number of subjects: 54
Study 23532011 — intervention group
Group type: COMPARATOR
Intervention: Contralesional sham stimulation followed by ipsilesional real intermittent theta burst stimulation (group B)
Number of subjects: 54
Study 23532011 — intervention group
Group type: COMPARATOR
Intervention: Contralesional real 1 Hz rTMS followed by ipsilesional sham stimulation (group C)
Number of subjects: 54
Study 23532011 — intervention group
Group type: COMPARATOR
Intervention: Bilateral sham-control procedures (group D)
Number of subjects: 54
Study 21146614 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over left DLPFC (20 min at 2 mA)
Number of subjects: 10
Study 21146614 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 10
Study 19064533 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.2 mg ELTP/d in a yogurt beverage for 8 weeks
Number of subjects: 275
Study 19064533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study 16221944 — intervention group
Group type: EXPERIMENTAL
Intervention: HIQuA recommendations
Number of subjects: 213
Study 16221944 — intervention group
Group type: COMPARATOR
Intervention: No query recommendations (Control)
Number of subjects: 213
Study 12680883 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg intranasal mometasone furoate (MF) once daily for 2 weeks
Number of subjects: 14
Study 12680883 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 14
Study 12680883 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg intranasal mometasone furoate (MF)
Number of subjects: 14
Study 10333933 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking training (WT)
Number of subjects: 169
Study 8951626 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% KNO3/Silica/NaF mouthwash
Number of subjects: 47
Study 8951626 — intervention group
Group type: COMPARATOR
Intervention: Silica/NaF mouthwash
Number of subjects: 47
Study 1683571 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic minitracheostomy
Number of subjects: 29
Study 1683571 — intervention group
Group type: COMPARATOR
Intervention: Control (no minitracheostomy)
Number of subjects: 29
Study 7030372 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol, 80 mg once a day
Number of subjects: 10
Study 7030372 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide, 100 mg once a day
Number of subjects: 10
Study 7030372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30132792 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottom-up image orientation
Number of subjects: 60
Study 30132792 — intervention group
Group type: COMPARATOR
Intervention: Top-down image orientation
Number of subjects: 60
Study 28086836 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-help intervention consisting of 10 text-based self-help sessions and one supportive email a week.
Number of subjects: 72
Study 28086836 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group for 12 weeks.
Number of subjects: 72
Study 28086836 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-help intervention.
Number of subjects: 72
Study 26064677 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric Titration Method (CTM)
Number of subjects: 162
Study 26064677 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control group
Number of subjects: 162
Study 23914211 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 mg kg(‐1) for the first 10 min, followed by continuous infusion of dexmedetomidine (0.2‐0.7 μg kg(‐1) h(‐1))
Number of subjects: 40
Study 23914211 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.2 mg kg(‐1) h(‐1) for the first 10 min, followed by continuous infusion of midazolam (0.05‐0.15 μg kg(‐1) h(‐1))
Number of subjects: 40
Study 20233198 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior administration of terbutaline
Number of subjects: 41
Study 18802369 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluid therapy (specific types not detailed, e.g., hydroxyethylstarch)
Number of subjects: 0
Study 18802369 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic therapy
Number of subjects: 0
Study 18802369 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care management strategies
Number of subjects: 0
Study 16482787 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneously-placed, round, saline-filled prosthesis with a textured surface (Siltex and Microcell implants)
Number of subjects: 107
Study 16482787 — intervention group
Group type: EXPERIMENTAL
Intervention: Reoperation for capsular contracture (open capsulotomy with or without implant exchange, closed compression capsulotomy)
Number of subjects: 107
Study 16482787 — intervention group
Group type: COMPARATOR
Intervention: Irradiated breasts
Number of subjects: 107
Study 16482787 — intervention group
Group type: COMPARATOR
Intervention: Large-pore implants
Number of subjects: 107
Study 12672710 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg oral calcium load with serum 25OHD at 86.5 nmol/L
Number of subjects: 2